(Reuters) - Takeda has long had its eye on gaining full control of TAP Pharmaceutical Products Inc., its venture with Abbott, but has been at odds with Abbott over the price.
Speculation has mounted recently, however, that a TAP buyout could happen this business year on reported comments by Abbott Chief Executive Miles White that the atmosphere may be right for Abbott to sell, and on co-marketing agreements between TAP and Takeda's wholly owned North American unit.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment